| Rank |
Status |
Study |
| 1 |
Not yet recruiting
|
The Impact of Genotype on Plasma and Cerebral Spinal Fluid Pharmacokinetics of Celecoxib in Children
| Condition: |
Pharmacokinetics of Celecoxib in Children |
| Intervention: |
Drug: Celecoxib |
| Outcome Measures: |
Change in Plasma and CSF concentrations of Celecoxib in children; Genomic testing and interpretation of the CYP2C9 genotype; Pediatric Quality of life Inventory; Pediatric cancer module; Multidimension Fatigue Inventory; Pediatric Pain Inventory; Demographics |
|
| 2 |
Not yet recruiting
|
Condrosulf vs Celebrex vs Placebo in the Treatment of Knee OA
| Condition: |
Knee Osteoarthritis |
| Interventions: |
Drug: chondroitin sulfate; Drug: celecoxib; Drug: placebo |
| Outcome Measures: |
Lequesne's Index; Pain (VAS in mm); MCII (minimal clinically important improvement); PASS (patient acceptable symptom state); Consumption of Paracetamol; Global efficacy assessment; Number of adverse events related to the treatments; Number of drop-outs due to AE (adverse event) related to the treatment |
|
| 3 |
Not yet recruiting
|
Intraviteral Celecoxib for Chronic Uveitis
| Condition: |
Inflammation |
| Intervention: |
Drug: Intravitreal Celecoxib |
| Outcome Measures: |
Safety; Efficacy |
|
| 4 |
Recruiting
|
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
| Condition: |
Unspecified Adult Solid Tumor, Protocol Specific |
| Interventions: |
Drug: capecitabine; Drug: celecoxib; Other: pharmacological study; Other: laboratory biomarker analysis; Other: pharmacogenomic studies |
| Outcome Measures: |
AUC of celecoxib on combination therapy (day 14) and AUC of celecoxib on celecoxib monotherapy(day 7); CYP2C9 genotype; Response rate; Drug-related toxicities; PK drug interaction model |
|
| 5 |
Not yet recruiting
|
Safety of Fluvastatin-Celebrex Association in Low-grade Optico-chiasmatic Gliomas
| Condition: |
Gliomas. |
| Interventions: |
Drug: Fluvastatine; Drug: Celebrex |
| Outcome Measures: |
Maximum tolerated dose (MTD) of Fluvastatine combined to a fixed-dose of Celebrex; Safety; Efficacy; Progression-free; Potential interactions between the two drugs |
|
| 6 |
Recruiting
|
Delaying Ossification and Improving Inflammation of Celebrex Plus/or Enbrel Treatment on Active Ankylosing Spondylitis
| Conditions: |
Inflammation; Ankylosing Spondylitis |
| Interventions: |
Drug: Celebrex; Drug: Enbrel; Drug: Enbrel plus Celebrex |
| Outcome Measures: |
the SPARCC score of spine and SI joint; mSASSS score of spine; ASAS20 response rate; ASAS20 response; ASAS40 response; ASAS70 response; ASAS5/6 response |
|
| 7 |
Recruiting
|
Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component
| Condition: |
Chronic Low Back Pain With a Neuropathic Component |
| Interventions: |
Drug: pregabalin and celecoxib; Drug: Placebo and celecoxib |
| Outcome Measures: |
Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain).; Benefit, Satisfaction, Willingness to Continue Measure (BSW); Patient Global Impression of Change (PGI-C); Daily Sleep Interference Rating Scale (SIRS); Hospital Anxiety and Depression Scale (HADS); Brief Pain Inventory-Short Form (BPI-sf) Score at Week X; Sleep Disturbance Subscale in the Medical Outcome Study (MOS) Sleep Scale at Week X |
|
| 8 |
Recruiting
|
Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women
| Condition: |
Obesity |
| Intervention: |
Drug: Celecoxib |
| Outcome Measure: |
To determine whether oral administration of Celebrex to obese women will reduce the PGE-M in urine |
|
| 9 |
Recruiting
|
Capecitabine and Celecoxib With or Without Radiation Therapy in Treating Patients With Colorectal Cancer Previously Treated With Fluorouracil
| Conditions: |
Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer |
| Interventions: |
Drug: capecitabine; Drug: celecoxib; Radiation: radiation therapy; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Radiation: intensity-modulated radiation therapy; Radiation: stereotactic body radiation therapy |
| Outcome Measures: |
Rate of CR, assessed according to CEA and CA 19-9 measurements and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; Relapse free survival in patients achieving CR; PFS as defined by true disease progression (new sites of disease); Overall survival; Best overall response rate, defined using RECIST 1.1; K-ras mutation status; Quality of life (QOL), assessed using the M.D. Anderson Symptom Inventory (MDASI); Adverse events defined as any condition that appears or worsens after the subject is enrolled in an investigational study, graded by numerical score according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 4.0 |
|
| 10 |
Recruiting
|
Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors
| Condition: |
Breast Cancer |
| Interventions: |
Drug: Celecoxib; Drug: Placebo; Drug: Cholecalciferol |
| Outcome Measures: |
PG synthesis and metabolism; Proliferative activity in the breast, as measured by MD cell morphology; Circulating levels of 25(OH)D, 1,25(OH)2D, and celecoxib |
|
| 11 |
Unknown †
|
Effectiveness of Celecoxib After Surgical Sperm Retrieval
| Condition: |
Pain |
| Interventions: |
Drug: Celecoxib; Drug: Sugar Pill |
| Outcome Measures: |
Level of pain; Bleeding complications |
|
| 12 |
Unknown †
|
A Trial Assessing the Outcome of Celecoxib Administration Versus Placebo Following Anterior Cruciate Ligament (ACL) Reconstruction
| Condition: |
Pain |
| Interventions: |
Drug: Celecoxib; Drug: Placebo |
| Outcome Measures: |
The primary outcome measure is to test the null hypothesis that Celecoxib perioperatively does not negatively influence the static testing of ACL reconstruction as measured by KT arthrometer at 2 years post op.; The 2nd outcome tested by this study is that the celecoxib group experiences equal pain control compared with the placebo group. |
|
| 13 |
Recruiting
|
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
| Condition: |
Neuroblastoma |
| Interventions: |
Drug: DFMO; Drug: Celecoxib; Drug: Cyclophosphamide; Drug: Topotecan |
| Outcome Measure: |
Number of participants with adverse events as a measure of safety and tolerability. |
|
| 14 |
Recruiting
|
Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)
| Condition: |
Lung Cancer |
| Intervention: |
Drug: Celecoxib |
| Outcome Measures: |
overall survival; progression-free survival |
|
| 15 |
Unknown †
|
Preemptive Analgesia Following Uterine Artery Embolization
| Conditions: |
Uterine Fibroids; Uterine Artery Embolization |
| Interventions: |
Drug: pregabalin/celecoxib; Drug: pregabalin/placebo; Drug: celecoxib/placebo; Drug: Placebo group |
| Outcome Measures: |
post operative pain control; Quality of life |
|
| 16 |
Unknown †
|
Arthroplasty Inflammation Prophylaxis With Celecoxib
| Condition: |
Postoperative Pain |
| Intervention: |
Drug: Celecoxib |
| Outcome Measures: |
Compare total pain rating in group receiving 7day celecoxib against in 1 dose celecoxib; 1. Comparison of pain rating VRS "When you woke up following surgery," and at 24 hours and 48 hours postoperatively in the two study groups; Comparison of patient reported maximum pain on VRS in the study groups. |
|
| 17 |
Recruiting
|
Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients
| Conditions: |
Arthritis; Cardiovascular Diseases; Cerebrovascular Disorders |
| Interventions: |
Drug: Celecoxib(drug); Drug: Naproxen(drug) |
| Outcome Measures: |
Recurrent ulcer bleeding within 78 weeks according to pre-specified criteria; Cardiovascular events |
|
| 18 |
Unknown †
|
A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer
| Condition: |
Prostate Cancer |
| Interventions: |
Drug: Taxotere; Drug: Celecoxib |
| Outcome Measures: |
Determine the effect of Taxotere and celecoxib on PSA and objective response in patients with HRPC; Evaluate the toxicity of the combination of celecoxib and Taxotere in patients with stage D3 prostate cancer.; Determine the effects of this regimen on quality of life.; Determine the survival of the patients treated |
|
| 19 |
Recruiting
|
Tramadol Versus Celecoxib for Reducing Pain in Outpatient Hysteroscopy
| Condition: |
Pain |
| Interventions: |
Drug: Tramadol; Drug: Celecoxib; Drug: Placebo |
| Outcome Measures: |
Pain perception during the procedure; Pain perception after the procedure |
|
| 20 |
Unknown †
|
Effect of Celecoxib on Transitional Pain After Outpatient Surgery
| Condition: |
Pain |
| Interventions: |
Drug: Celebrex; Drug: placebo |
| Outcome Measures: |
visual analogue score for pain; severity of nausea |
|
